BIBP’s Group ACYW135 Meningococcal Polysaccharide Vaccine was approved for marketing

Big News!

BIBP’s Group ACYW135 Meningococcal Polysaccharide Vaccine

was approved for marketing!

It enriches CNBG’s vaccine products for human use

and provides more protection for the prevention of epidemic meningitis in China!

Recently, Sinopharm CNBG, Beijing Institute of Biological Products Co., Ltd. (hereinafter referred to as "BIBP")’s Group ACYW135 Meningococcal Polysaccharide Vaccine was officially approved for marketing.

BIBP’s Group ACYW135 Meningococcal Polysaccharide Vaccine successfully passed GMP compliance inspection in 2021, obtained the drug registration certificate and drug authorization number in September 2022, and was officially approved for marketing.

At present, Group A and C Meningococcal Polysaccharide Vaccine has been included in the National Immunization Program, but it can not prevent group Y and W135 meningococcal infections. With the increase of international exchanges in China, the cases of group W135 meningococcal infections have been found in several provinces (autonomous regions and municipalities), and the possibility of localized epidemics of meningococcal group Y and W135 in China is gradually increasing. Group ACYW135 Meningococcal Polysaccharide Vaccine is suitable for high-risk groups of children and adults aged 2 to 50 years, and can effectively prevent epidemic meningitis caused by groups A, C, Y and W135 meningococcal infections, providing more effective protection for the public.